*仅供医学专业人士阅读参考众所周知，T细胞通过主要组织相容性复合体（MHC）识别靶细胞。一直以来，我们都认为，所有细胞表面都存在的MHC-I类分子，仅调节CD8阳性T细胞和NK细胞介导的免疫反应；而只存在于抗原呈递细胞表面的MHC-II类分子，则调节 ...

Researchers reveal that CD4+ T cells can kill cancer cells lacking MHC I by triggering ferroptosis, challenging established ...

Recent analyses show that Omicron variants of SARS-CoV-2 more strongly suppress major histocompatibility complex class I expression than previous versions of the virus. Throughout the pandemic, the ...

In a paradigm-breaking study, researchers have discovered a novel way the immune system, specifically T cells, attack their ...

A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer. Major histocompatibility complex (MHC) class ...

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...

Researchers in Japan and the United States have developed a new technology to increase visibility of cancer cells to the immune system using CRISPR. The findings were led by Koichi Kobayashi, ...

ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...

Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...